Danicopan
- Generic Name
- Danicopan
- Brand Names
- Voydeya
- Drug Type
- Small Molecule
- Chemical Formula
- C26H23BrFN7O3
- CAS Number
- 1903768-17-1
- Unique Ingredient Identifier
- JM8C1SFX0U
- Background
Danicopan is under investigation in clinical trial NCT03459443 (A Proof of Concept Study for a 12 Month Treatment in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)).
- Associated Conditions
- -
- Associated Therapies
- -
Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis
- Conditions
- Interventions
- First Posted Date
- 2024-06-07
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT06449001
Danicopan Early Access Program
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Registration Number
- NCT05982938
Potential Drug Interaction Between ALXN2040 and Rosuvastatin
- First Posted Date
- 2023-02-01
- Last Posted Date
- 2023-04-14
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT05708573
- Locations
- πΊπΈ
Clinical Trial Site, Baltimore, Maryland, United States
A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH
- Conditions
- Interventions
- First Posted Date
- 2022-05-25
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT05389449
- Locations
- π¬π§
Research Site, London, United Kingdom
A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults
- Conditions
- Interventions
- First Posted Date
- 2021-11-05
- Last Posted Date
- 2021-11-05
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT05109390
- Locations
- πΊπΈ
Clinical Trial Site, Tempe, Arizona, United States
A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
- First Posted Date
- 2021-08-25
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 365
- Registration Number
- NCT05019521
- Locations
- π¬π§
Research Site, Southampton, United Kingdom
A Study of the Cardiac Effects of Danicopan in Healthy Adults
- Conditions
- Interventions
- First Posted Date
- 2021-08-23
- Last Posted Date
- 2021-08-23
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT05016206
- Locations
- πΊπΈ
Clinical Trial Site, Tempe, Arizona, United States
ACTIV-5 / Big Effect Trial (BET-C) for the Treatment of COVID-19
- First Posted Date
- 2021-08-03
- Last Posted Date
- 2023-06-08
- Target Recruit Count
- 201
- Registration Number
- NCT04988035
- Locations
- πΊπΈ
Great Lakes Clinical Trials, Chicago, Illinois, United States
πΊπΈNuvance Health Danbury Hospital - Infectious Disease, Danbury, Connecticut, United States
πΊπΈKern Medical Center, Bakersfield, California, United States
Study of Danicopan in Participants With Normal Kidney Function and Participants With Kidney Dysfunction
- First Posted Date
- 2021-06-23
- Last Posted Date
- 2021-06-23
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT04935294
- Locations
- πΊπΈ
Clinical Trial Site, Saint Paul, Minnesota, United States
Study of Multiple Doses of Danicopan in Healthy Participants
- First Posted Date
- 2021-05-17
- Last Posted Date
- 2021-05-17
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT04889690
- Locations
- π³πΏ
Clinical Trial Site, Auckland, New Zealand
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.